VULSCi002-A-6
The cell line is not validated yet.
CIGLi001-A-6
General
Cell Line |
|
| hPSCreg name | CIGLi001-A-6 |
| Cite as: | CIGLi001-A-6 |
| Alternative name(s) |
VULSCi002-A-6
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 21st June 2025 |
| User feedback | |
Provider |
|
| Generator | Vilnius University (VULSC) |
| Owner | Vilnius University (VULSC) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA118573734 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Hispanic |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
Passes test for quality control as mentioned by supplier vcf File: 802 30F datasheet.pdf The company, SYNTHEGO, that is supplying the cell line to us, mentions that quality control assessment is done and sequence validation data can be provided upon request |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA114652490 |
Ethics
Also have a look at the ethics information for the parental line
CIGLi001-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CIGLi001-A.
|
|
Reprogramming method |
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemFit
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
XX
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.